Abstract
Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biologic drivers in antibody production. We used a six-compartment mechanistic model to describe a 20-week time course of humoral immune responses in 56 non-human primates (NHPs) elicited by vaccination with Ad26.COV2.S according to either a single-dose regimen (1 × 1011 or 5 × 1010 viral particles [vp]) or a two-dose homologous regimen (5 × 1010 vp) given in an interval of 4 or 8 weeks. Humoral immune responses were quantified by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike–specific binding antibody concentrations as determined by spike protein–enzyme-linked immunosorbent assay. The mechanistic model adequately described the central tendency and variability of binding antibody concentrations through 20 weeks in all vaccination arms. The estimation of mechanistic modeling parameters revealed greater contribution of the antibody production mediated by short-lived cells as compared with long-lived cells in driving the peak response, especially post second dose when a more rapid peak response was observed. The antibody production mediated by long-lived cells was identified as relevant for generating the first peak and for contributing to the long-term time course of sustained antibody concentrations in all vaccination arms. The findings contribute evidence on the key biologic components responsible for the observed time course of vaccine-induced humoral immunity in NHPs and constitute a step toward defining immune biomarkers of protection against SARS-CoV-2 that might translate across species.
SIGNIFICANCE STATEMENT We demonstrate the adequacy of a mechanistic modeling approach describing the time course of binding antibody concentrations in non-human primates (NHPs) elicited by different dose levels and regimens of Ad26.COV2.S. The findings are relevant for informing the mechanism-based accounts of vaccine-induced humoral immunity in NHPs and translational research efforts aimed at identifying immune biomarkers of protection against SARS-CoV-2 infection.
Footnotes
- Received January 23, 2023.
- Accepted July 19, 2023.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement [HHSO100201700018C].
Anna Dari is the employee of Janssen Research and Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson. Laura Solforosi is the employee of Janssen Research and Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson. Ramon Roozendaal is the employee of Janssen Research and Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson. Richard M.W. Hoetelmans is the employee of Janssen Research and Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson. Juan-José Pérez-Ruixo is the employee of Janssen Research and Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson. Muriel Boulton is the employee of Janssen Research and Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson.
↵This article has supplemental material available at jpet.aspetjournals.org.
- Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|